COPD: SPIRIVA RESPIMAT is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema, the maintenance treatment of associated dyspnoea and for prevention of exacerbations.
Asthma: SPIRIVA RESPIMAT is indicated as add on maintenance treatment for the improvement of FEV1 in adult patient with severe asthma who remain symptomatic on inhaled fluticasone.